Saint Herblain (France), September 9, 2020 – Valneva SE (“Valneva”), a specialty vaccine company, today announced the signing of a new contract, lasting up to three years, with the U.S. government Department of Defense (DoD) for the supply of its Japanese encephalitis (JE) vaccine, IXIARO®.
The new contract spans a total of three years (one base year, plus two option years) with a base-year value of $61 million. The DoD has the option to purchase a total of $76 million – $105 million worth of IXIARO® across the two option years. Deliveries for the base-year will commence in the fourth quarter 2020.
Franck Grimaud, Chief Business Officer of Valneva commented, “We are very pleased with this new contract including the longer duration of up to three years – a clear demonstration of the clinical need for personnel deployed to JE endemic areas. The U.S. military has been using IXIARO® for the past ten years and we are excited to continue to help protect military personnel, their families, civilian government service personnel, and government contractors from this potentially deadly disease.”
IXIARO® is the only JE vaccine approved by the U.S. Food and Drug Administration (FDA), having been developed through a cooperative research and development agreement with the Walter Reed Army Institute of Research. Valneva markets and distributes IXIARO® directly to the U.S. military and U.S. private market.
Über Japanische Enzephalitis
Japanische Enzephalitis (JE) ist eine tödliche Infektionskrankheit, die vor allem in Asien vorkommt. 70.000 Fälle von JE treten schätzungsweise jedes Jahr in Asien auf, obwohl die tatsächliche Zahl der Fälle aufgrund von zu geringen Angaben in ländlichen Gebieten und anderen Faktoren wahrscheinlich viel höher liegt. JE ist in etwa 30 % der Personen, die Symptome zeigen, tödlich und die Hälfte der Überlebenden trägt permanente Hirnschäden davon. Die Krankheit ist in Südostasien, Indien und China, einer Region mit mehr als 3 Milliarden Einwohnern, endemisch. In nur einem Monat im Jahr 2005 wurden mehr als 1.200 Kinder während einer Epidemie in Uttar Pradesh, Indien und Nepal getötet.
Über Valneva SE
Valneva is a specialty vaccine company focused on prevention against diseases with major unmet needs. Valneva’s portfolio includes two commercial vaccines for travelers: IXIARO®/JESPECT® indicated for the prevention of Japanese encephalitis and DUKORAL® indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by ETEC. The Company has various vaccines in development including unique vaccines against Lyme disease, chikungunya and COVID-19. Valneva has operations in Austria, Sweden, the United Kingdom, France, Canada and the US with over 500 employees. For more information, visit www.valneva.com and follow the Company on LinkedIn.
Kontakte für Investoren und Medien
Laetitia Bachelot-Fontaine Director Investor Relations & Corporate Communications M +33 (0)6 4516 7099 investors@valneva.com |
Teresa Pinzolits Corporate Communications Specialist T +43 (0)1 20620 1116 communications@valneva.com |
Zukunftsgerichtete Aussagen
This press release contains certain forward-looking statements relating to the business of Valneva, including with respect to the progress, timing and completion of research, development and clinical trials for product candidates, the ability to manufacture, market, commercialize and achieve market acceptance for product candidates, the ability to protect intellectual property and operate the business without infringing on the intellectual property rights of others, estimates for future performance and estimates regarding anticipated operating losses, future revenues, capital requirements and needs for additional financing. In addition, even if the actual results or development of Valneva are consistent with the forward-looking statements contained in this press release, those results or developments of Valneva may not be indicative of their in the future. In some cases, you can identify forward-looking statements by words such as “könnte,” “sollte,” “könnte” “erwartet,” “antizipiert,” “glaubt,” “beabsichtigt,” “schätzt,” “strebt an,” “zielt darauf ab,” or similar words. These forward-looking statements are based largely on the current expectations of Valneva as of the date of this press release and are subject to a number of known and unknown risks and uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievement expressed or implied by these forward-looking statements. In particular, the expectations of Valneva could be affected by, among other things, uncertainties involved in the development and manufacture of vaccines, unexpected clinical trial results, unexpected regulatory actions or delays, competition in general, currency fluctuations, the impact of the global and European credit crisis, and the ability to obtain or maintain patent or other proprietary intellectual property protection. In light of these risks and uncertainties, there can be no assurance that the forward-looking statements made during this presentation will in fact be realized. Valneva is providing the information in these materials as of this press release, and disclaim any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.